Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Chemoimmunotherapy Combined With Autologous NK Cell Therapy for the Treatment of Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma

NCT07375563 is registered in ClinicalTrials.gov with Federal Research Institute of Pediatric Hematology, Oncology and Immunology as lead sponsor.

NCT NCT07375563
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07375563 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Chemoimmunotherapy Combined With Autologous NK Cell Therapy for the Treatment of Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma
Lead sponsor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase
Phase 3
Overall status
Recruiting
Start date
November 19, 2025
Completion date
November 19, 2028
Enrollment
5 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ganglioneuroblastoma, neuroblastoma (nb)